The Claim
In patients who have received a heart transplant, the use of PCSK9 inhibitors is associated with stable levels of calcineurin inhibitors, indicating no significant pharmacokinetic interaction between these two drug classes when treatment with PCSK9 inhibitors is initiated.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you've had a heart transplant and start taking a PCSK9 inhibitor for cholesterol, it probably won't mess with your anti-rejection medication levels.
See the scientific wording
In heart transplant recipients, PCSK9 inhibitor use is associated with stable calcineurin inhibitor levels, suggesting no major pharmacokinetic interaction between these drug classes during treatment initiation.
What the research says
1 studyThe study looked at whether PCSK9 inhibitors affect levels of other drugs used after heart transplants, and found that those levels stayed steady, which supports the idea that the drugs don’t interfere with each other.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.